J&J sales top forecast, helped by hepatitis drug

October 14, 2014 By MassDevice Leave a Comment

Nobel Biocare’s Q2 profits double as it fields buyout interest

August 21, 2014 By Brad Perriello Leave a Comment

ConvaTec said to explore 2015 sale

August 19, 2014 By Brad Perriello Leave a Comment

Medtronic’s Q1 earnings beat The Street on modest sales bump

August 19, 2014 By Brad Perriello Leave a Comment

Diabetes: DexCom’s revenues jump 64% in Q2

August 11, 2014 By Arezu Sarvestani Leave a Comment

Diabetes devices maker DexCom (NSDQ:DXCM) got a lot of love from Wall Street after issuing its latest quarterly report, with DXCM shares gaining 14.5% since last week.

EnteroMedics’ losses widen as it chases FDA approval

August 8, 2014 By Arezu Sarvestani Leave a Comment

Minnesota-based EnteroMedics (NSDQ:ETRM) gained modestly this week after announcing its latest financial report, even though the company missed the mark by a penny.

Strong Q4, $750M buyback give CareFusion a boost

August 8, 2014 By Arezu Sarvestani Leave a Comment

Strong Q2, $750M buyback give CareFusion a boost

CareFusion (NYSE:CFN) posted a stellar 4th-quarter, posting double-digit growth in revenues and earnings and beating Wall Street’s estimates.

Masimo sinks as Q2 misses the mark

August 8, 2014 By Arezu Sarvestani Leave a Comment

California device maker Masimo (NSDQ:MASI) got no Wall Street love this week after announcing results for its most recent quarter.

Baxano: Strong Q2, new patents can’t appease Wall Street

August 8, 2014 By Arezu Sarvestani Leave a Comment

Baxano: Strong Q2, $10M raise, new patents and clinical trial can't appease Wall Street

Baxano Surgical (NSDQ:BAXS) just can’t seem to do right by Wall Street.

Thoratec’s new study, $30M buyback can’t stave off Wall Street exodus after dismal Q2

August 7, 2014 By Arezu Sarvestani Leave a Comment

New study, $30M buyback can't save Thoratec from Wall Street exodus after dismal Q2

Circulatory devices maker Thoratec (NSDQ:THOR) took a major hit yesterday as a bleak 2nd-quarter reports and a lowered outlook on the year sent its stock into a nosedive.

Struggling Alere plans to shed some skin after rough Q2

August 6, 2014 By Arezu Sarvestani Leave a Comment

Struggling Alere plans to ditch some units

Massachusetts-based device maker Alere (NYSE:ALR) said in its quarterly earnings call that it’ll shed some of its business units in order to reorganize in the wake of a missed quarter.

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

J&J sales top forecast, helped by hepatitis drug

Nobel Biocare’s Q2 profits double as it fields buyout interest

ConvaTec said to explore 2015 sale

Medtronic’s Q1 earnings beat The Street on modest sales bump

Diabetes: DexCom’s revenues jump 64% in Q2

EnteroMedics’ losses widen as it chases FDA approval

Strong Q4, $750M buyback give CareFusion a boost

Masimo sinks as Q2 misses the mark

Baxano: Strong Q2, new patents can’t appease Wall Street

Thoratec’s new study, $30M buyback can’t stave off Wall Street exodus after dismal Q2

Struggling Alere plans to shed some skin after rough Q2

MASSDEVICE MEDICAL NETWORK

MASSDEVICE